Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 2/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 4/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.39 |
| ▸ | PDE2A | O00408 | 3/20 | 0.39 |
| ▸ | KIF11 | P52732 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30617195 | 1.00 | DAO (0.46) | DAORXRARXRBRXRGIDO1 | |
| SCHEMBL2272131 | 0.87 | RXRA (0.50) | DAORXRARXRBRXRGKIF11 | |
| SCHEMBL2111621 | 0.86 | IDO1 (0.40) | DAOIDO1HTR2ASLC6A4KCNH2 | |
| SCHEMBL11537101 | 0.83 | IDO1 (0.43) | DAOIDO1HTR2ASLC6A4KCNH2 | |
| SCHEMBL7969520 | 0.81 | PON1 (0.47) | RXRARXRBPOLBMAPT | |
| SCHEMBL21945440 | 0.81 | DAO (0.47) | DAORXRARXRBRXRGIDO1 | |
| SCHEMBL12603811 | 0.81 | DAO (0.51) | DAORXRARXRBRXRGIDO1 | |
| SCHEMBL171171 | 0.79 | DAO (0.46) | DAORXRARXRBRXRGIDO1 | |
| SCHEMBL5325907 | 0.79 | IDO1 (0.58) | DAOIDO1HTR2ASLC6A4KCNH2 | |
| SCHEMBL5112247 | 0.79 | DAO (0.46) | DAORXRARXRBRXRGIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435078-B2 | Pyridazinones and methods of use thereof | GFB (ABC), LLC (US) | 2025-10-07 | — | — | US | disclosed |
| EP-4304588-A1 | COMPOUNDS HAVING TETRAHYDROINDOLIZINE-1-CARBOXAMIDE AS BCL-2 INHIBITORS | Eil Therapeutics, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| CN-116981458-A | Compounds with tetrahydroindole-1-carboxamides as BCL-2 inhibitors | 伊尔治疗学股份有限公司 | 2023-10-31 | — | — | CN | disclosed |
| US-11697650-B2 | Compounds having tetrahydroindolizine-1-carboxamide as BCL-2 inhibitors | Eil Therapeutics, Inc. (US) | 2023-07-11 | — | — | US | disclosed |
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2023-06-29 | — | — | US | disclosed |
| US-20220289745-A1 | COMPOUNDS HAVING TETRAHYDROINDOLIZINE-1-CARBOXAMIDE AS BCL-2 INHIBITORS | EIL TERAPEUTICS, INC. | 2022-09-15 | — | — | US | disclosed |
| EP-3684364-A2 | PYRIDAZINONES AND METHODS OF USE THEREOF | Goldfinch Bio, Inc. (US) | 2020-07-29 | — | — | EP | disclosed |
| WO-2019055966-A2 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
| US-20080051418-A1 | Arylalkanoic Acid Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-28 | — | — | US | disclosed |
| EP-1829863-A1 | ARYLALKANOIC ACID DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2007-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | PDXK, ATP6V1B1, REN | DAO 1077/4885RXRA 893/4885RXRB 961/4885 |
| US-20220289745-A1 | COMPOUNDS HAVING TETRAHYDROINDOLIZINE-1-CARBOXAMIDE AS BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2A1 | DAO 1267/4885RXRA 3271/4885RXRB 3131/4885 |
| US-20080051418-A1 | Arylalkanoic Acid Derivative | INSR, NPY1R, GPR119 | DAO 267/4885RXRA 5/4885RXRB 11/4885 |
| US-12435078-B2 | Pyridazinones and methods of use thereof | PDXK, ATP6V1B1, REN | DAO 1077/4885RXRA 893/4885RXRB 961/4885 |
| US-11697650-B2 | Compounds having tetrahydroindolizine-1-carboxamide as BCL-2 inhibitors | BCL2, BCL2L1, BCL2A1 | DAO 1267/4885RXRA 3271/4885RXRB 3131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.